A phase II trial of bevacizumab in myelodysplastic syndromes (int-1, int-2 and high risk according to IPSS [International Prognostic Scoring System]) with excess of marrow blasts.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 08 Dec 2011 Biomarkers information updated
- 07 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Dec 2007 New trial record.